147 related articles for article (PubMed ID: 14758126)
1. Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma.
Alexandrakis MG; Passam FH; Kyriakou DS; Dambaki K; Niniraki M; Stathopoulos E
Am J Clin Oncol; 2004 Feb; 27(1):8-13. PubMed ID: 14758126
[TBL] [Abstract][Full Text] [Related]
2. Ki-67 Immunostaining and its Correlation with Microvessel Density in Patients with Mutiple Myeloma.
Himani B; Meera S; Abhimanyu S; Usha R
Asian Pac J Cancer Prev; 2016; 17(5):2559-64. PubMed ID: 27268630
[TBL] [Abstract][Full Text] [Related]
3. [Proliferative activity of myeloma cells determined by Ki-67 antibody: biological and clinical significance].
Marković O; Marisavljević D; Cemerikić V; Vidović A; Bakrac M; Perunicić M; Suvajdzić N; Colović M
Vojnosanit Pregl; 2005 Jan; 62(1):33-8. PubMed ID: 15715347
[TBL] [Abstract][Full Text] [Related]
4. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma: relationship to proliferative activity and prognostic significance.
Markovic O; Marisavljevic D; Cemerikic V; Suvajdzic N; Milic N; Colovic M
Med Oncol; 2004; 21(1):73-80. PubMed ID: 15034217
[TBL] [Abstract][Full Text] [Related]
7. The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma.
Tsirakis G; Pappa CA; Kaparou M; Boula A; Katsomitrou V; Xekalou A; Kyriakaki S; Alexandrakis MG
Tumour Biol; 2013 Apr; 34(2):859-64. PubMed ID: 23242610
[TBL] [Abstract][Full Text] [Related]
8. [Expression and clinical significance of beta-catenin in multiple myeloma].
Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
[TBL] [Abstract][Full Text] [Related]
9. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
[TBL] [Abstract][Full Text] [Related]
10. Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulin.
Schambeck CM; Bartl R; Höchtlen-Vollmar W; Wick M; Lamerz R; Fateh-Moghadam A
Am J Clin Pathol; 1996 Jul; 106(1):64-8. PubMed ID: 8701935
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III.
Niemöller K; Jakob C; Heider U; Zavrski I; Eucker J; Kaufmann O; Possinger K; Sezer O
J Cancer Res Clin Oncol; 2003 Apr; 129(4):234-8. PubMed ID: 12700896
[TBL] [Abstract][Full Text] [Related]
12. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
13. Significance of Proliferation Markers and Prognostic Factors in Egyptian Patients with Multiple Myeloma.
Abdelgawad IA; Radwan NH; Shafik RE; Shokralla HA
Asian Pac J Cancer Prev; 2016; 17(3):1351-5. PubMed ID: 27039771
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow microvascular density and angiogenic growth factors in multiple myeloma.
Alexandrakis MG; Passam FJ; Ganotakis E; Dafnis E; Dambaki C; Konsolas J; Kyriakou DS; Stathopoulos E
Clin Chem Lab Med; 2004; 42(10):1122-6. PubMed ID: 15552270
[TBL] [Abstract][Full Text] [Related]
15. High density of tryptase-positive mast cells in patients with multiple myeloma: correlation with parameters of disease activity.
Devetzoglou M; Vyzoukaki R; Kokonozaki M; Xekalou A; Pappa CA; Papadopoulou A; Alegakis A; Androulakis N; Alexandrakis MG
Tumour Biol; 2015 Nov; 36(11):8491-7. PubMed ID: 26026586
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of bone marrow histology in multiple myeloma.
Subramanian R; Basu D; Dutta TK
Indian J Cancer; 2009; 46(1):40-5. PubMed ID: 19282565
[TBL] [Abstract][Full Text] [Related]
17. Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma.
Terpstra WE; Lokhorst HM; Blomjous F; Meuwissen OJ; Dekker AW
Br J Haematol; 1992 Sep; 82(1):46-9. PubMed ID: 1419801
[TBL] [Abstract][Full Text] [Related]
18. [Serum LDH and myeloma. Correlation with the degree of bone marrow infiltration].
Ogea García JL; Blanco Molina MA; Andrés P; Muñoz R; Jiménez Alonso J; Pérez Jiménez F
Rev Esp Oncol; 1985; 32(2):207-13. PubMed ID: 3843455
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of a histologic classification system applied in bone marrow biopsies from patients with multiple myeloma: a histopathological evaluation of biopsies from 153 untreated patients.
Sailer M; Vykoupil KF; Peest D; Coldewey R; Deicher H; Georgii A
Eur J Haematol; 1995 Mar; 54(3):137-46. PubMed ID: 7720832
[TBL] [Abstract][Full Text] [Related]
20. Expression of proliferating cell nuclear antigen (PCNA) in multiple myeloma: its relationship to bone marrow microvessel density and other factors of disease activity.
Alexandrakis MG; Passam FH; Pappa CA; Dambaki C; Sfakiotaki G; Alegakis AK; Kyriakou DS; Stathopoulos E
Int J Immunopathol Pharmacol; 2004; 17(1):49-56. PubMed ID: 15000866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]